Sentien Biotechnologies, a privately-owned company established in 2008, is focused on developing novel cell therapies to restore immune system balance and transform treatment options for patients with systemic inflammatory diseases. Their flagship product, SBI-101, immobilizes MSCs in an extracorporeal device, allowing for sustained and controlled dosage of anti-inflammatory and regenerative properties. This innovative blood conditioning approach has been proven to enhance exposure and extend therapeutic activity of MSCs, providing a unique treatment option that cannot be achieved through direct injection or intravenous infusion. Headquartered in Lexington, Massachusetts, Sentien Biotechnologies aims to harness the power of cell therapy and innovative drug delivery systems to address a wide range of acute inflammatory diseases.